Adagene Inc. (ADAG)
NasdaqGM · USD · Healthcare · Biotechnology
$2.49 (+3.32%) as of
Key statistics
- Market cap
- 167.19M
- Forward P/E
- -4.45
- EPS (TTM)
- -0.3800
- Dividend yield
- 0.00%
- 52-week range
- 1.3000 – 4.8500
- Beta
- 0.54
- Revenue (TTM)
- 9.29M
- Profit margin
- -220.77%
- Analyst target
- $9.91
- Volume
- 91.20k
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suzhou, China
- Employees
- 128
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.